• Epidemiology and risk factors
• 30 min
  1. Epidemiology of COPD

  • Dr. David Mannino
• 36 min
  2. COPD in never smokers

  • Dr. Sundeep Salvi
• 43 min
  3. Genetics of chronic obstructive pulmonary disease (COPD)

  • Prof. Martin Tobin
• Phenotypes of COPD
• 44 min
  4. COPD and asthma: similarities and differences

  • Prof. Peter Barnes
• Pathophysiology and mechanisms of COPD
• 43 min
  5. The pathology of chronic obstructive pulmonary disease

  • Prof. James Hogg
• 63 min
  6. The continuum of COPD: a physiological perspective

  • Prof. Denis O'Donnell
• 47 min
  7. Inflammatory and immune mechanisms in COPD

  • Prof. Peter Barnes
• 44 min
  8. Mechanisms of COPD exacerbations and relation to exacerbation therapy

  • Prof. Wisia Wedzicha
• 39 min
  9. Protease-antiprotease balance

  • Prof. Robert Stockley
• Therapy and management
• 42 min
  10. Updates in chronic obstructive pulmonary disease (COPD)

  • Dr. Omar S. Usmani
• 45 min
  11. Long-acting bronchodilators in COPD

  • Prof. Bart Celli
• 54 min
  12. Treatment of COPD exacerbations

  • Prof. Antonio Anzueto
• 25 min
  13. Pulmonary rehabilitation: history, promise and problems

  • Prof. Richard Casaburi
• 29 min
  14. Lung volume reduction: advances in COPD

  • Dr. Nick Hopkinson
• 35 min
  15. New pharmacological therapies for COPD

  • Prof. Peter Barnes
• 32 min
  16. The Salford lung study in COPD

  • Dr. Dave Leather
• COPD case studies
• 11 min
  17. COPD treatment case I: COPD with “bronchitis attacks”

  • Dr. Janwillem Kocks
• 13 min
  18. COPD treatment case II: COPD with asthma as child

  • Dr. Janwillem Kocks
• 12 min
  19. COPD treatment case III: COPD with pre-diabetes

  • Dr. Janwillem Kocks
• 48 min
  20. Tailoring care for advanced COPD

  • Prof. Wissam Chatila
• Archived Lectures *These may not cover the latest advances in the field
• 59 min
  21. Alpha-1 antitrypsin deficiency: state of the art

  • Dr. Jamie Stoller
• 34 min
  22. Oxidative stress in COPD

  • Prof. William MacNee
• 24 min
  23. Managing co-morbidity in COPD

  • Dr. John Hurst
• 40 min
  24. Clinical phenotypes of COPD

  • Prof. Jørgen Vestbo
• 27 min
  25. Pulmonary rehabilitation: focusing on rehabilitative exercise

  • Prof. Richard Casaburi
• 36 min
  26. Genetics of COPD

  • Prof. Ian Hall

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. A definition of COPD
3. Pathology of COPD
4. Air trapping in COPD
5. Amplification of inflammation in COPD
6. Cellular mechanisms of COPD
7. NF-kappaB in COPD
8. Elastase activity of macrophages in COPD
9. Effects of MMP-9
10. Macrophages in COPD
11. GRO-alpha (CXCL1) in COPD
12. Alveolar macrophages in COPD
13. Macrophage phagocytosis in COPD (1)
14. Macrophage phagocytosis in COPD (2)
15. Macrophage phagocytosis: model
16. Microtubular function
17. CD8 cells in COPD
18. CXCR3 chemokines
19. Evolution of inflammation in COPD
20. Th17 cells
21. Th17 cells in COPD
22. Cytokines in induced sputum in COPD
23. Reduced effect of corticosteroids in COPD
24. Amplification and steroid resistance
25. HDAC2 in COPD lung
26. HDAC2 and steroid responsiveness in COPD
27. Corticosteroid resistance in COPD (1)
28. Corticosteroid resistance in COPD (2)
29. PI3K-Akt pathway
30. Theophylline as HDAC activator
31. Theophylline restores steroid response
32. Reversal of smoke-induced inflammation
33. COPD patients: corticosteroids + theophylline
34. How does theophylline restore HDAC
35. PI3K-delta inhibition in vivo
36. PI3K-delta null mice
37. Nrf2 and antioxidant gene regulation
38. COPD comorbidities
39. Conclusions

Topics Covered

• Amplification of inflammation in COPD
• Inflammatory cells involved in COPD
• Role of macrophages in orchestrating inflammation
• Defective macrophage phagocytosis in COPD
• Mechanism of corticosteroid resistance in COPD
• Role of Nrf2

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.